Developing a new class of cancer immunotherapies
IMV Inc. is a clinical-stage biopharmaceutical company. They’re developing a new class of cancer immunotherapies and vaccines to treat infectious diseases such as COVID-19. Further, the company is deeply committed to making immunotherapy and vaccines more effective, more broadly applicable, and more widely available to patients.
“We are developing a new type of treatment for cancer. It’s based on immunotherapy. It is using your your own immune system to cure cancer,” says CEO Frederic Ors.
The DPX platform uses a versatile technology that generates a targeted, robust and sustained immune response. Moreover, thanks to its unique “no release” delivery system, their proprietary DPX delivery platform can be formulated with peptide antigens to induce a specific, robust, and sustained immune response. Additionally, IMV is leveraging this mechanism of action to generate “first-in-class” T cell therapies for patients facing cancer. In the context of infectious diseases, the DPX platform can also be formulated with B cell epitopes to target virus’ specific regions like spike proteins of the SARS-CoV2.
For more information on IMV Inc. (TSX: IMV, Nasdaq: IMV) please fill out the form below.